SOPHIA ANTIPOLIS, France – January 22, 2024 │ The quarterly report for the Q4 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. What’s new this quarter? Q4 2023 IP Activity overview The IP activity during Q4 2023 is consistent[…]
SOPHIA ANTIPOLIS, France – January 16, 2024 │ The last quarterly report for the 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. As we leave behind another year, we look back on the mRNA therapeutic patenting activity! Q4 2023[…]
SOPHIA ANTIPOLIS, France – November 15, 2023 │ KnowMade’s Therapeutic mRNA Patent Monitor was presented at the 11th mRNA health conference in Berlin (October 31 to November 2, 2023) through the poster N°49 (High resolution PDF download here). Abstract Therapeutic mRNA, which became widely known as vaccine against COVID-19, are expected to be applicated to[…]
SOPHIA ANTIPOLIS, France – November 06, 2023 │ReNAgadeTherapeutics, a company founded in 2021 and based in Cambridge, presented preclinical data demonstrating a new and proprietary method of delivering mRNA to extra-hepatic tissues in non-human primate using lipid nanoparticles (LNPs) at the 11th International mRNA Health Conference, taking place from October 31 to November 2, 2023[…]